Cancer Biomarkers Market by Tumor (Breast, Lung, Prostate), Type (Protein & Genetic Biomarkers), Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay), Application (Diagnostic, Drug Discovery, Prognostic) & Geography - Global Forecast to 2020

Date: August 28, 2015
Pages: 259
Price:
US$ 5,650.00
License [?]:
Publisher: MarketsandMarkets
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G4B61763966EN
Leaflet:

Download PDF Leaflet

Cancer Biomarkers Market by Tumor (Breast, Lung, Prostate), Type (Protein & Genetic Biomarkers), Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay), Application (Diagnostic, Drug Discovery, Prognostic) & Geography - Global Forecast to 2020
In this report, the biomarkers market is segmented on the basis of product, type, application, disease indication, and geography. The product segments included in this report are consumables, services, software. The type segments included in this report are safety biomarkers, efficacy biomarkers, and validation biomarkers. The applications segments included in this report are diagnostics development, drug discovery and development, personalized medicine, disease risk assessment, and other applications. The disease indications segments included in this report are cancer, cardiovascular disorders, neurological disorders, immunological disorders, and other diseases.

The geographic segments included in this report are North America, Europe, Asia, and the Rest of the World (RoW).

The growth of this market is mainly driven by increasing healthcare expenditure, increase in R&D spending, increasing utility of biomarkers for diagnostics, increasing number of CROs, the low cost of clinical trials in developing countries, and new initiatives for biomarker research. The high growth potential in emerging markets and the increasing adoption of personalized medicine and companion diagnostics provides new growth opportunities to players in the biomarkers market.

A combination of bottom-up and top-down approaches were used to calculate the market sizes and growth rates of the global biomarkers market and its subsegments. Secondary information was used to identify overall revenue, geographic reach, and product portfolios of market players. Estimates of the biomarkers market segment revenues were validated through primary interviews. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates.

The report provides qualitative insights on key market shares, growth rates, and market drivers for important subsegments. It maps the market sizes and growth rates of each segment and identifies segments poised to witness rapid growth. The report includes company profiles and a competitive landscape of the biomarkers market. The company profiles include the financial performances, product portfolios, and developments of each company, whereas, the competitive landscape covers the growth strategies adopted by industry players over the last three years. The report also includes analyses of industry developments such as acquisitions, agreements, collaborations & partnerships; new product launches; and other developments.

Reasons to Buy the Report:

The report will enable both established firms and new entrants to gauge the pulse of the market and make important strategic growth decisions.

The report provides insights on the following:
  • Product Development/Innovation: Product portfolios of the top players in the biomarkers market. Detailed insights on upcoming technologies, R&D activities, and new product launches in the biomarkers market
  • Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of the leading players in the biomarkers market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various biomarkers across geographies
  • Market Diversification: Exhaustive information about new products, recent developments, and investments in the biomarkers market
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
  1.3.1 MARKETS COVERED
  1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY AND PRICING
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 RESEARCH APPROACH
2.2 MARKET SIZE ESTIMATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 KEY DATA FROM SECONDARY SOURCES
2.6 KEY DATA FROM PRIMARY SOURCES
  2.6.1 KEY INDUSTRY INSIGHTS
2.7 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 GROWTH POTENTIAL OF THE GLOBAL CANCER BIOMARKERS MARKET
4.2 ASIA-PACIFIC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY (2014)
4.3 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL CANCER BIOMARKERS MARKET
4.4 GLOBAL CANCER BIOMARKERS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET SEGMENTATION
  5.2.1 BY TYPE
  5.2.2 BY TUMOR TYPE
  5.2.3 BY PROFILING TECHNOLOGIES
  5.2.4 BY APPLICATION
5.3 MARKET DYNAMICS
  5.3.1 DRIVERS
    5.3.1.1 Technological advancements
    5.3.1.2 Rising Incidence of cancer
    5.3.1.3 Enhanced accuracy and speed of diagnosis
    5.3.1.4 Increasing use of cancer biomarkers in drug discovery and development
    5.3.1.5 Increasing research on cancer biomarkers
    5.3.1.6 FDA support for biomarker development
  5.3.2 RESTRAINTS
    5.3.2.1 Poorly suited regulatory and reimbursement systems
    5.3.2.2 High capital investment and low benefit-cost ratio
    5.3.2.3 Technical issues related to sample collection and storage
  5.3.3 OPPORTUNITITES
    5.3.3.1 Personalized medicine
    5.3.3.2 Companion diagnostics
    5.3.3.3 Emerging economies
  5.3.4 CHALLENGES
    5.3.4.1 Proving clinical validity and utility of biomarker-based tests leading to their insufficient acceptance

6 INDUSTRY INSIGHTS

6.1 INTRODUCTION
6.2 INDUSTRY TRENDS
6.3 PORTER’S FIVE FORCES ANALYSIS
  6.3.1 THREAT OF NEW ENTRANTS
  6.3.2 THREAT OF SUBSTITUTES
  6.3.3 BARGAINING POWER OF SUPPLIERS
  6.3.4 BARGAINING POWER OF BUYERS
  6.3.5 INTENSITY OF COMPETITIVE RIVALRY

7 GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE

7.1 INTRODUCTION
7.2 LUNG CANCER
7.3 COLORECTAL CANCER
7.4 PROSTATE CANCER
7.5 CERVICAL CANCER
7.6 OTHER CANCERS

8 CANCER BIOMARKERS MARKET, BY TYPE

8.1 INTRODUCTION
8.2 PROTEIN BIOMARKERS
8.3 GENETIC BIOMARKERS
8.4 OTHER CANCER BIOMARKERS

9 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY

9.1 INTRODUCTION
9.2 OMICS TECHNOLOGIES
  9.2.1 PROTEOMICS
  9.2.2 GENOMICS
    9.2.2.1 Next Generation Sequencing (NGS)
    9.2.2.2 Microarrays
    9.2.2.3 Polymer Chain Reaction (PCR)
  9.2.3 OTHER OMICS TECHNOLOGIES
9.3 IMAGING TECHNOLOGIES
  9.3.1 ULTRASOUND
  9.3.2 COMPUTED TOMOGRAPHY (CT)
  9.3.3 MAGNETIC RESONANCE IMAGING (MRI)
  9.3.4 POSITRON EMISSION TOMOGRAPHY (PET)
  9.3.5 MAMMOGRAPHY
9.4 IMMUNOASSAYS
  9.4.1 IMMUNOHISTOCHEMISTRY (IHC)
  9.4.2 FLOW CYTOMETRY
  9.4.3 ELISA
9.5 CYTOGENETICS
  9.5.1 IN SITU HYBRIDIZATION (ISH)
  9.5.2 OTHERS
9.6 BIOINFORMATICS

10 CANCER BIOMARKERS MARKET, BY APPLICATION

10.1 INTRODUCTION
10.2 DIAGNOSTICS
10.3 DRUG DISCOVERY AND DEVELOPMENT
10.4 PROGNOSTICS
10.5 RISK ASSESSMENT
10.6 OTHER APPLICATIONS

11 CANCER BIOMARKERS MARKET, BY REGION

11.1 INTRODUCTION
11.2 NORTH AMERICA
  11.2.1 U.S.
  11.2.2 CANADA
11.3 EUROPE
  11.3.1 GERMANY
  11.3.2 U.K.
  11.3.3 FRANCE
  11.3.4 ITALY
  11.3.5 SPAIN
  11.3.6 REST OF EUROPE (ROE)
11.4 ASIA-PACIFIC
  11.4.1 JAPAN
  11.4.2 CHINA
  11.4.3 INDIA
  11.4.4 REST OF APAC
11.5 REST OF THE WORLD (ROW)
  11.5.1 LATIN AMERICA
  11.5.2 MIDDLE EAST AND AFRICA

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW
12.2 MARKET SHARE ANALYSIS
12.3 COMPETITIVE SITUATIONS AND TRENDS.
  12.3.1 NEW PRODUCT LAUNCHES
  12.3.2 AGREEMENTS
  12.3.3 ACQUISITIONS
  12.3.4 COLLABORATIONS
  12.3.5 OTHERS

13 COMPANY PROFILES

(Overview, Financials, Products & Services, Strategy, & Developments)*

13.1 INTRODUCTION
13.2 ABBOTT LABORATORIES
13.3 AFFYMETRIX, INC.
13.4 ILLUMINA, INC.
13.5 QIAGEN N.V.
13.6 ROCHE DIAGNOSTICS LTD.
13.7 AGILENT TECHNOLOGIES, INC.
13.8 QUEST DIAGNOSTICS INC.
13.9 MERCK & CO. INC.
13.10 HOLOGIC, INC.
13.11 BECTON, DICKINSON AND COMPANY

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

14 APPENDIX

14.1 INSIGHTS OF INDUSTRY EXPERTS
14.2 DISCUSSION GUIDE
14.3 RECENT DEVELOPMENTS, BY MARKET PLAYER, 2011-2015
14.4 AVAILABLE CUSTOMIZATIONS
14.5 INTRODUCTION RT: REAL-TIME MARKET INTELLIGENCE
14.6 RELATED REPORTS

LIST OF TABLES

Table 1 TECHNOLOGICAL ADVANCEMENTS AND RISING INCIDENCE OF CANCER ARE DRIVING THE GROWTH OF THE CANCER BIOMARKERS MARKET
Table 2 POORLY SUITED REGULATORY AND REIMBURSEMENT SYSTEMS OF BIOMARKER TESTS ARE RESTRAINING THE GROWTH OF CANCER BIOMARKERS MARKET
Table 3 PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS PRESENT AN ARRAY OPPORTUNITITES FOR THE GROWTH OF CANCER BIOMARKERS MARKET.
Table 4 INSUFFICIENT ACCEPTANCE, PROVING CLINICAL VALIDITY AND UTILITY OF BIOMARKER-BASED TESTS ARE A MAJOR CHALLENGE IN THE CANCER BIOMARKERS MARKET
Table 5 GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013–2020 (USD MILLION)
Table 6 GLOBAL BREAST CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 7 GLOBAL LUNG CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 8 GLOBAL COLORECTAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 9 GLOBAL PROSTATE CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 10 GLOBAL CERVICAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 11 GLOBAL OTHER CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 12 CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
Table 13 PROTEIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 14 GENETIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 15 OTHER CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 16 CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013–2020 (USD MILLION)
Table 17 GLOBAL OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 18 GLOBAL OMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 19 GLOBAL PROTEOMICS MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 20 GLOBAL GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 21 GLOBAL GENOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY (USD MILLION)
Table 22 GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 23 GLOBAL MICROARRAYS MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 24 GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 25 GLOBAL OTHER OMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 26 GLOBAL IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 27 GLOBAL IMAGING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 28 GLOBAL ULTRASOUND MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 29 GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 30 GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 31 GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 32 GLOBAL MAMMOGRAPHY MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 33 GLOBAL IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 34 GLOBAL IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 35 GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 36 GLOBAL FLOW CYTOMETRY MARKET, BY COUNTRY, 2013–2020 (USD MILLION)
Table 37 GLOBAL ELISA MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 38 GLOBAL CYTOGENETICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 39 GLOBAL CYTOGENETICS MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 40 GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 41 GLOBAL OTHER CYTOGENETICS TESTS MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 42 GLOBAL BIOINFORMATICS MARKET SIZE, BY COUNTRY, 2013–2020, USD MILLION
Table 43 GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 44 GLOBAL CANCER BIOMARKERS MARKET SIZE FOR DIAGNOSTICS APPLICATIONS, BY COUNTRY/REGION, 2013-2020 (USD MILLION)
Table 45 GLOBAL CANCER BIOMARKERS MARKET SIZE FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY COUNTRY/REGION, 2013-2020 (USD MILLION)
Table 46 GLOBAL CANCER BIOMARKERS MARKET SIZE FOR PROGNOSTICS APPLICATIONS, BY COUNTRY/REGION, 2013-2020 (USD MILLION)
Table 47 GLOBAL CANCER BIOMARKERS MARKET SIZE FOR RISK ASSESSMENT APPLICATIONS, BY COUNTRY/REGION, 2013-2020 (USD MILLION)
Table 48 GLOBAL CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY/REGION, 2013-2020 (USD MILLION)
Table 49 GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)
Table 50 NORTH AMERICA:CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 51 NORTH AMERICA: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013–2020 (USD MILLION)
Table 52 NORTH AMERICA: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 53 NORTH AMERICA: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013–2020 (USD MILLION)
Table 54 NORTH AMERICA: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 55 NORTH AMERICA: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 56 NORTH AMERICA: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 57 NORTH AMERICA: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 58 NORTH AMERICA: CYTOGENETICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 59 NORTH AMERICA: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 60 U.S.: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013–2020 (USD MILLION)
Table 61 U.S.: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 62 U.S.: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013–2020 (USD MILLION)
Table 63 U.S.: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 64 U.S.: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 65 U.S.: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 66 U.S.: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 67 U.S.: CYTOGENETICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 68 U.S.: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 69 CANADA: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013–2020 (USD MILLION)
Table 70 CANADA: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 71 CANADA: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013–2020 (USD MILLION)
Table 72 CANADA: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 73 CANADA: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 74 CANADA: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 75 CANADA: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 76 CANADA: CYTOGENETICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 77 CANADA: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 78 EUROPE:CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 79 EUROPE: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013–2020 (USD MILLION)
Table 80 EUROPE: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 81 EUROPE: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013–2020 (USD MILLION)
Table 82 EUROPE: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 83 EUROPE: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 84 EUROPE: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 85 EUROPE: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 86 EUROPE: CYTOGENETICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 87 EUROPE: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 88 GERMANY: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013–2020 (USD MILLION)
Table 89 GERMANY: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 90 GERMANY: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013–2020 (USD MILLION)
Table 91 GERMANY: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 92 GERMANY: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 93 GERMANY: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 94 GERMANY: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 95 GERMANY: CYTOGENETICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 96 GERMANY: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 97 U.K.: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013–2020 (USD MILLION)
Table 98 U.K.: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 99 U.K.: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013–2020 (USD MILLION)
Table 100 U.K.: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 101 U.K.: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 102 U.K.: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 103 U.K.: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 104 U.K.: CYTOGENETICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 105 U.K.: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 106 FRANCE: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013–2020 (USD MILLION)
Table 107 FRANCE: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 108 FRANCE: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013–2020 (USD MILLION)
Table 109 FRANCE: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 110 FRANCE: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 111 FRANCE: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 112 FRANCE: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 113 FRANCE: CYTOGENETICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 114 FRANCE: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 115 ITALY: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013–2020 (USD MILLION)
Table 116 ITALY: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 117 ITALY: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013–2020 (USD MILLION)
Table 118 ITALY: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 119 ITALY: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 120 ITALY: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 121 ITALY: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 122 ITALY: CYTOGENETICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 123 ITALY: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 124 SPAIN: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013–2020 (USD MILLION)
Table 125 SPAIN: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 126 SPAIN: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013–2020 (USD MILLION)
Table 127 SPAIN: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 128 SPAIN: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 129 SPAIN: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 130 SPAIN: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 131 SPAIN: CYTOGENETICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 132 SPAIN: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 133 ROE: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013–2020 (USD MILLION)
Table 134 ROE: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 135 ROE: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013–2020 (USD MILLION)
Table 136 ROE: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 137 ROE: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 138 ROE: IMAGING TECHNOLOGIES MARKET SIZE, 2013–2020 (USD MILLION)
Table 139 ROE: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 140 ROE: CYTOGENETICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 141 ROE: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 142 ASIA-PACIFIC: CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 143 ASIA-PACIFIC: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013–2020 (USD MILLION)
Table 144 ASIA-PACIFIC: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 145 ASIA-PACIFIC: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013–2020 (USD MILLION)
Table 146 ASIA-PACIFIC: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 147 ASIA-PACIFIC: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 148 ASIA-PACIFIC: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 149 ASIA-PACIFIC: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 150 ASIA-PACIFIC: CYTOGENETICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 151 ASIA-PACIFIC: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 152 JAPAN: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013–2020 (USD MILLION)
Table 153 JAPAN: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 154 JAPAN: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013–2020 (USD MILLION)
Table 155 JAPAN: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 156 JAPAN: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 157 JAPAN: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 158 JAPAN: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 159 JAPAN: CYTOGENETICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 160 JAPAN: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 161 CHINA: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013–2020 (USD MILLION)
Table 162 CHINA: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 163 CHINA: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013–2020 (USD MILLION)
Table 164 CHINA: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 165 CHINA: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 166 CHINA: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 167 CHINA: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 168 CHINA: CYTOGENETICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 169 CHINA: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 170 INDIA: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013–2020 (USD MILLION)
Table 171 INDIA: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 172 INDIA: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013–2020 (USD MILLION)
Table 173 INDIA: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 174 INDIA: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 175 INDIA: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 176 INDIA: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 177 INDIA: CYTOGENETICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 178 INDIA: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 179 REST OF APAC: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013–2020 (USD MILLION)
Table 180 REST OF APAC: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 181 REST OF APAC: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013–2020 (USD MILLION)
Table 182 REST OF APAC: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 183 REST OF APAC: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 184 REST OF APAC: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 185 REST OF APAC: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 186 REST OF APAC: CYTOGENETICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 187 REST OF APAC: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 188 ROW: CANCER BIOMARKERS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)
Table 189 ROW: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013–2020 (USD MILLION)
Table 190 ROW: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 191 ROW: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013–2020 (USD MILLION)
Table 192 ROW: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 193 ROW: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 194 ROW: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 195 ROW: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 196 ROW: CYTOGENETICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 197 ROW: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 198 LATIN AMERICA: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013–2020 (USD MILLION)
Table 199 LATIN AMERICA: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 200 LATIN AMERICA: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013–2020 (USD MILLION)
Table 201 LATIN AMERICA: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 202 LATIN AMERICA: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 203 LATIN AMERICA: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 204 LATIN AMERICA: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 205 LATIN AMERICA: CYTOGENETICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 206 LATIN AMERICA: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 207 MIDDLE EAST AND AFRICA: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013–2020 (USD MILLION)
Table 208 MIDDLE EAST AND AFRICA: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 209 MIDDLE EAST AND AFRICA: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013–2020 (USD MILLION)
Table 210 MIDDLE EAST AND AFRICA: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 211 MIDDLE EAST AND AFRICA: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 212 MIDDLE EAST AND AFRICA: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 213 MIDDLE EAST AND AFRICA: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 214 MIDDLE EAST AND AFRICA: CYTOGENETICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 215 MIDDLE EAST AND AFRICA: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 216 GROWTH STRATEGY MATRIX, 2011-2015
Table 217 NEW PRODUCT LAUNCHES, 2012-2015
Table 218 AGREEMENTS, 2012-2015
Table 219 ACQUISITIONS, 2012-2015
Table 220 COLLABORATIONS
Table 221 OTHER DEVELOPMENTS, 2012-2015

LIST OF FIGURES

Figure 1 GLOBAL CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY
Figure 2 CANCER BIOMARKERS MARKET, BY CANCER TYPE
Figure 3 CANCER BIOMARKERS MARKET, BY TYPE
Figure 4 CANCER BIOMARKERS MARKET, BY APPLICATION
Figure 5 RESEARCH DESIGN
Figure 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 7 BOTTOM-UP APPROACH
Figure 8 TOP-DOWN APPROACH
Figure 9 DATA TRIANGULATION METHODOLOGY
Figure 10 GLOBAL CANCER BIOMARKERS MARKET, BY TYPE, 2015 VS. 2020 (USD MILLION)
Figure 11 GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015 VS. 2020 (USD MILLION)
Figure 12 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015 VS. 2020 (USD MILLION)
Figure 13 CANCER BIOMARKERS MARKET, BY APPLICATION, 2015 VS. 2020 (USD MILLION)
Figure 14 GEOGRAPHIC ANALYSIS: GLOBAL CANCER BIOMARKERS MARKET
Figure 15 RISING INCIDENCES OF CANCER TO DRIVE MARKET GROWTH
Figure 16 OMICS TECHNOLOGIES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA-PACIFIC CANCER BIOMARKERS MARKET
Figure 17 THE CHINA IS GROWING AT THE FASTEST GEOGRAPHIC REGION IN CANCER BIOMARKERS MARKET IN 2014
Figure 18 NORTH AMERICA TO DOMINATE THE GLOBAL CANCER BIOMARKERS MARKET DURING THE FORECAST PERIOD
Figure 19 CHINA TO REGISTER HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
Figure 20 CANCER BIOMARKERS MARKET, BY TYPE
Figure 21 CANCER BIOMARKERS MARKET, BY CANCER TYPE
Figure 22 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGIES
Figure 23 CANCER BIOMARKERS MARKET, BY APPLICATION
Figure 24 CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITITES, AND CHALLENGES
Figure 25 GLOBAL CANCER INCIDENCE, 2008–2025
Figure 26 INCREASING USE OF BIOMARKERS FOR THE DEVELOPMENT OF PERSONALIZED MEDICINE IS THE KEY TREND IN THE CANCER BIOMARKERS INDUSTRY
Figure 27 PORTER’S FIVE FORCES ANALYSIS
Figure 28 GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2015 VS. 2020 (USD MILLION)
Figure 29 GENETIC BIOMARKERS ARE EXPECTED TO GROW AT THE HIGHEST CAGR IN THE FORECAST PERIOD
Figure 30 OMICS TECHNOLOGIES WILL CONTINUE TO DOMINATE THE GLOBAL CANCER BIOMARKERS MARKET IN 2020
Figure 31 GLOBAL CANCER BIOMARKERS MARKET, BY APPLICATION, 2015 VS. 2020
Figure 32 CANCER BIOMARKERS MARKET: GEOGRAPHIC SNAPSHOT (2015–2020)
Figure 33 CHINA TO HOLD THE HIGHEST GROWTH POTENTIAL FOR ALMOST ALL SEGMENTS IN THE GLOBAL CANCER BIOMARKERS MARKET
Figure 34 NORTH AMERICA MARKET SNAPSHOT:
Figure 35 GERMANY WAS THE LARGEST MARKET FOR CANCER BIOMARKERS IN EUROPE IN 2014
Figure 36 ASIA-PACIFIC CANCER BIOMARKERS MARKET SNAPSHOT: CHINA AND INDIA ARE THE MOST LUCRATIVE MARKETS FOR CANCER BIOMARKERS
Figure 37 NEW PRODUCT LAUNCHES WAS THE KEY GROWTH STRATEGY ADOPTED BETWEEN 2012 AND 2015
Figure 38 GLOBAL CANCER BIOMARKERS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014
Figure 39 BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES WAS THE KEY STRATEGY
Figure 40 GEOGRAPHICAL REVENUE MIX OF KEY PLAYERS IN THE MARKET
Figure 41 ABBOTT LABORATORIES: COMPANY SNAPSHOT
Figure 42 AFFYMETRIX, INC.: COMPANY SNAPSHOT
Figure 43 ILLUMINA, INC.: COMPANY SNAPSHOT
Figure 44 QIAGEN N.V.: COMPANY SNAPSHOT
Figure 45 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
Figure 46 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
Figure 47 QUEST DIAGNOSTICS: COMPANY SNAPSHOT
Figure 48 MERCK & CO, INC.: COMPANY SNAPSHOT
Figure 49 HOLOGIC, INC.: COMPANY SNAPSHOT
Figure 50 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
Skip to top


Ask Your Question

Cancer Biomarkers Market by Tumor (Breast, Lung, Prostate), Type (Protein & Genetic Biomarkers), Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay), Application (Diagnostic, Drug Discovery, Prognostic) & Geography - Global Forecast to 2020
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: